Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies.
ADC drugs have both the powerful killing effects of the small molecule and tumor targeting properties of antibody. The recent technology breakthrough has led to nine new ADC approvals in the past three years for cancer treatment.
As one of the most sophisticated class of drug modalities, ADC has several components including antibody, payload and linkers with a concerted mechanism of functions. New structures are emerging regularly to hit the new clinical applications, and the indications are also moving rapidly from oncology to non-oncology fields.
MediLink Therapeutics was formed by experienced scientists from both small and large molecule drug development fields. The management team has collectively put over 20 new compounds into clinical developments, 3 of them are antibody drug conjugates. The team also has strong background in corporate governance and capital operations.
YL202 was approved by CDE for clinical trials
YL202 project IND has received approval from the FDA
YL201 was approved by CDE for clinical trials
Establishment of Singapore subsidiary and YL project enrolled first subject in clinical trial
YL201 project IND has received approval from the FDA
Completed $70 million Series B financing
YL202 project into pharmacology and toxicology
Subsidiaries in Boston and Hong Kong were established
YL201 project entered the formal stage of pharmacology and toxicology
Start the design of 18,000 production sites
Suzhou production subsidiary Eigong Source, Shanghai subsidiary was established
Suzhou Biobay research and development site put into use
Completed A round of 350 million RMB financing
Product IP Layout
Initiate research and development site design
Two collaborations were reached
Key personnel in place
Two projects were approved
Develop toxin Linker design